Monitoring of Patients With Low-grade Gliomas Using Circulating miRNA
With around 3,400 cases per year in France, diffuse gliomas are the most common primary tumours of the central nervous system. Their grade varies from 2 to 4. Whatever the grade, their prognosis is poor, because tumour recurrence is systematic, because no personalised medicine is available for the treatment of these ca
| Condition(s) | Glioma, miRNA, Low-grade Glioma, Biomarkers |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | With around 3,400 cases per year in France, diffuse gliomas are the most common primary tumours of the central nervous system. Their grade varies from 2 to 4. Whatever the grade, their prognosis is poor, because tumour recurrence is systematic, because no personalised medicine is available for the treatment of these cancers, and because the tools for monitoring recurrence are imperfect. Treatment of diffuse gliomas is based on removal of as much of the tumour as possible, whatever its grade. Surgery is followed by radiotherapy and chemotherapy depending on the grade and quality of the excision. In the event of recurrence, the patient may be offered second-line chemotherapy or further surgery. During and after treatment, patients are regularly monitored by MRI in order to detect any recurre |
| Who can participate | Inclusion Criteria: * Major patient * Suffered from a grade 2-3 diffuse glioma * Surgery in the neurosurgery department of Caen University Hospital * Patient affiliated to a social security scheme * Patient followed at Caen University Hospital * No opposition from the patient Exclusion Criteria: * Patients who have undergone biopsy (lack of material for the study, limited value of monitoring for these patients without surgical excision) * Patients with grade 1 circumscribed glioma * Patients with grade 4 glioma * Other non-glial histologies, glioneuronal histology * Minor patients * Patient not affiliated to a social security scheme * Major under guardianship or protected |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University Hospital, Caen |
| Locations | Caen, France |
| Start date | 2024-04-25 |
| NCT ID | NCT06610851 |
| Official listing | https://clinicaltrials.gov/study/NCT06610851 |